Phase II study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk. Primary objective is the evaluation of the pathological complete response after 8 instillation of gemcitabine. 46 patients are requested.

Inclusion criteria

• Histologically or cytologically confirmed diagnosis of NSCLC
• Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage IIIB (only N3 supraclavicular or T4 for pleural effusion) or Stage IV according to the revised International Staging System
• Patients must have at least one measurable lesion
• WHO Performance Status 0 or 1
• Adequate Organ Function

Exclusion criteria:

• Prior systemic chemotherapy or immunotherapy including neoadjuvant or adjuvant treatments
• Prior radiotherapy for NSCLC
• Patients with symptomatic brain metastases or with leptomeningeal disease. However, patients with symptomatic brain metastases who become asymptomatic under corticosteroids treatment can enter the study
• Current peripheral neuropathy NCI grade 2